Five VELDONA® Pet items are now available
New supplements will launch in Taiwan in July ahead of the scheduled global release, assisting to keep resistance for countless animals
Ainos sets its sights on going into the $137 billion United States family pet market
SAN DIEGO, CA / ACCESSWIRE / June 14, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) (“Ainos”, or the “Company”), a varied medtech business concentrated on the advancement of unique point-of-care screening, low-dose interferon therapies, and artificial RNA-driven preventative medication, today revealed the launch of 2 brand-new VELDONA® Pet cytoprotein supplement items. VELDONA® Pet Shiny, created to support animals’ eye health, and VELDONA® Pet Slim, developed to help handle body weight and weight-related health concerns, will be introduced next month in Taiwan. The release marks the last action in the rollout of Ainos’ VELDONA® Pet line of product. With all 5 items introduced effectively, the Company is poised to press towards its objective of reaching US$20 million in sales from its VELDONA® Pet supplement line throughout 2024.
VELDONA® Pet Shiny and VELDONA® Pet Slim reinforce Ainos’ existing line of VELDONA® Pet health supplements, which likewise consists of VELDONA® Pet Lohas for psychological wellness, VELDONA® Pet Soothing for eliminating pain brought on by allergic reactions, and VELDONA® Pet Cytoprotein supplement for keeping resistance, oral care, and gum and skin health. All VELDONA® Pet items were at first introduced in Taiwan, with strategies in location to begin marketing them around the world in the future.
VELDONA® Pet Shiny supplies relief for eye pain and supports the body’s healing from conditions such as keratitis and ocular herpes infections. A research study carried out by Colorado State University showed that interferon might decrease pain from eye infections and promotes recovery conditions such as keratitis and eye herpes. VELDONA® Pet Shiny supplies eye security without the possible disadvantages of conventional treatment approaches.
VELDONA® Pet Slim can help handle body weight and address metabolic imbalances emerging from excess body weight. Studies have actually shown that interferon can prevent diet-induced weight problems and cellular swelling connected with weight problems. Supplementing with interferon reveals guarantee in handling body weight and dealing with metabolic imbalances arising from excess body weight.
Chun-Hsien Tsai, Ainos’ Chairman of the Board, President, and Chief Executive Officer, commented, “The unveiling of our latest VELDONA® Pet supplements showcases the significant development we have actually made in changing our business. In a couple of brief months, we have actually moved from marketing COVID-19 test sets to developing the structure we require to end up being a really varied and prominent health care options company. These latest VELDONA® Pet items are the next action in our development, however definitely aren’t the last.”
“As we broaden our portfolio and market our items in areas around the world, we draw closer to our target of reaching US$20 million in VELDONA® Pet supplement sales in 2024,” Mr. Tsai included. “Our ultimate objective is to bring VELDONA Pet to the U.S., where overall family pet expenses surpassed $137 billion in 2022. The work we have actually put in through years of research study and advancement is flourishing, and we anticipate the 2nd half of 2023 will be an important and amazing time for our business. I think Ainos is well-positioned for the next chapter of our story.”
About VELDONA® Pet
Based on Ainos’ low-dose oral interferon-alpha (“IFNα”) solution, VELDONA® Pet cytoprotein supplements are backed by many research study studies and scientific trials, and are produced with first-rate products in an extremely licensed food-grade plant. VELDONA® preserves resistance and adds to gum and skin health, eliminating allergic reactions and decreasing tension in cats and dogs. Interferon, a kind of cytoprotein, is naturally produced by human and animals. When cells are gotten into by foreign particles, immune signaling particles inform surrounding cells. Once nearby cells receive the interferon’s protein signal through their surface area receptors, they start and regulate the body immune system to safeguard felines and dogs from gum and skin illness, allergic reactions, stress-related conditions, eye pain from infections, and weight imbalance brought on by metabolic dysfunction.
A medical research study, sponsored by Ainos and carried out by the Agricultural Technology Research Institute in Taiwan, has actually shown that VELDONA® assists keep the body immune systems of cats and dogs. Numerous research studies have actually reported the advantages of interferons in keeping gum health and skin health, eliminating pain brought on by allergic reactions and eye infections, calming psychological tension, and stabilizing weight from metabolic condition in cats and dogs. VELDONA® Pet’s objective is to keep resistance for countless animals with the first-rate items.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. is a varied medtech business participated in establishing ingenious medical innovations for point-of-care screening and safe and unique medical treatment for a broad series of illness signs. In addition to its exclusive therapies utilizing low-dose non-injectable interferon, Ainos has actually likewise broadened its item portfolio to consist of Volatile Organic Compounds (VOC) and COVID-19 POCTs. Powered by its AI Nose platform, the lead POCT prospect, Ainos Flora, is a telehealth-friendly POCT for ladies’s health and specific typical STIs. To learn more, see https://www.ainos.com.
Follow Ainos on Twitter (@AinosInc) and LinkedIn to remain current.
Forward-Looking Statements
This news release includes “positive declarations” about Ainos within the significance of the safe harbor arrangements of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking declarations can be determined by the usage of words such as “expect,” “think,” “price quote,” “anticipate,” “mean,” “strategy,” “anticipate,” “task,” “target,” “future,” “likely,” “technique,” “anticipate,” “may,” “assistance,” “possible,” “outlook,” “projection,” “should,” “will” or other comparable words or expressions. Similarly, declarations that explain the Company’s goals, strategies or objectives are, or might be, positive declarations. Forward-looking declarations are based just on the Company’s existing beliefs, expectations, and presumptions. Forward-looking declarations go through intrinsic unpredictabilities, dangers, and modifications in situations that are hard to anticipate and a number of which are beyond the Company’s control. The Company’s real outcomes might vary materially from those shown in the positive declarations.
Important elements that might trigger the Company’s real outcomes to vary materially from the forecasts, projections, quotes and expectations gone over in this news release consist of, to name a few, the cost of production and sales capacity of the prepared drug treatments revealed in this news release; the Company’s reliance on profits from the sale of COVID-19 test sets; the Company’s restricted money and history of losses; the Company’s capability to attain success; the Company’s capability to raise extra capital to continue the Company’s item advancement; the capability to properly anticipate the future operating outcomes of the Company; the capability to advance Ainos’ existing or future item prospects through scientific trials, obtain marketing approval and eventually advertise any item prospects the Company establishes; the capability to obtain and keep regulative approval of Ainos item prospects; hold-ups in finishing the advancement and commercialization of the Company’s existing and future item prospects, which might lead to increased expenses to the Company, hold-up or restrict the capability to produce income and negatively impact the business, monetary condition, outcomes of operations and potential customers of the Company; extreme competitors and quickly advancing innovation in the Company’s market that might exceed its innovation; consumer need for the services and products the Company establishes; the effect of competitive or alternative items, innovations and rates; interruption in research study and advancement centers; suits and other claims by 3rd parties or examinations by different regulative companies governing the Company’s operations; possible cybersecurity attacks; increased requirements and expenses associated with cybersecurity; the Company’s capability to understand the advantages of 3rd party licensing arrangements; the Company’s capability to obtain and keep copyright security for Ainos item prospects; compliance with relevant laws, policies and tariffs; and the Company’s success in handling the development. A more total description of these threat elements and others is consisted of in the “Risk Factors” area of Ainos’ most recent Annual Report on Form 10-K and other reports submitted with the U.S. Securities and Exchange Commission, a number of which dangers are beyond the Company’s control. In addition to the dangers explained above and in the Company’s Form 10-K, other unidentified or unforeseeable elements likewise might trigger real outcomes to vary materially from the forecasts, projections, quotes and expectations gone over in this news release.
The positive declarations made in this news release are specifically certified in their totality by the foregoing cautionary declarations. Ainos carries out no commitment to, and specifically disclaims any such commitment to, openly update or modify any positive declaration to show altered presumptions, the incident of expected or unexpected occasions or modifications to the future outcomes in time or otherwise, other than as needed by law.
Investor Relations Contact
ICR, LLC
Robin Yang
Tel: +1 646-224-6971
Email: [email protected]
SOURCE: Ainos, Inc.
